Faro raised a $37 million Series B to accelerate clinical trials using AI, targeting a known bottleneck: the time and complexity required to operate through trial execution rather than to design molecules. The startup’s funding indicates that investor attention is shifting from discovery tooling to trial optimization workflows—where data pipelines, monitoring, and operational forecasting drive speed. The company’s emphasis on AI-enabled approaches for trial acceleration reflects growing competition among companies trying to reduce cycle times and improve feasibility without compromising scientific rigor. The funding round also underscores that clinical execution technologies are increasingly treated as core infrastructure. For the sector, the key development is the continued movement of capital toward “post-discovery” AI—analytics and automation designed to manage enrollment, operations, and evidence generation across trial timelines.